RESEARCH ARTICLE

REVISED Association of thrombocytopenia with splenomegaly in malaria patients in East Kalimantan: A cross-sectional, retrospective study [version 3; peer review: 2 approved]

Loly R.D. Siagian¹, Vera M. Lumbantoruan², Nurul Hasanah³, Fransiska A. Sihotang⁴, Carta A. Gunawan⁵

¹Department of Clinical Pathology, Faculty of Medicine, Medical Faculty of Mulawarman University and Abdul Wahab Public Hospital, East Kalimantan, Indonesia

²Department of Dermato Venereology, Faculty of Medicine, Medical Faculty of Mulawarman University and Abdul Wahab Public Hospital, East Kalimantan, Indonesia

³Department of Histology, Faculty of Medicine, Medical Faculty of Mulawarman University, East Kalimantan, Indonesia

⁴Department of Physiology, Faculty of Medicine, Mulawarman University, East Kalimantan, Indonesia

⁵Department of Internal Medicine, Faculty of Medicine, Medical Faculty of Mulawarman University and Abdul Wahab Public Hospital, East Kalimantan, Indonesia

V3 First published: 21 Nov 2018, 7:1832
<https://doi.org/10.12688/f1000research.16606.1>
 Second version: 14 Aug 2019, 7:1832
<https://doi.org/10.12688/f1000research.16606.2>
 Latest published: 29 Oct 2019, 7:1832
<https://doi.org/10.12688/f1000research.16606.3>

Abstract

Background: Malaria still presents as a major health problem in Indonesia and specifically in East Kalimantan. One common sign found in malaria patient is thrombocytopenia, the mechanism of which is still unclear. Several studies have suggested some mechanisms, one of which is splenomegaly. This study aimed to discover the association between thrombocytopenia and splenomegaly of malaria patients in East Kalimantan.

Methods: This study was a descriptive retrospective study with clinical and laboratory data obtained from the medical records of malaria patients in four major public hospitals from January 2015 to July 2018. The association between thrombocytopenia with splenomegaly was analysed using Chi-Square test.

Results: A total of 215 patients were included; 189 male (87.9%) and 26 female (12.1%). The etiologic agents found in these patients were *Plasmodium vivax* (43.2%), *Plasmodium falciparum* (42.8%), and mixed infection (*Plasmodium falciparum* and *Plasmodium vivax*) (4.6%). The thrombocyte count was normal in 28 patients (13%) and decreased in 187 patients (87%). Among patients with thrombocytopenia, the percentage of mild, moderate and severe thrombocytopenia was 18.2%, 43.8% and 33%, respectively. Splenomegaly was found in only 11 patients (5.1%). We found no association between thrombocytopenia with splenomegaly ($p=0.61$).

Open Peer Review

Approval Status

	1	2
version 3		
(revision)
29 Oct 2019		view
version 2		
(revision)
14 Aug 2019		view
version 1		
21 Nov 2018		view

1. **Jontari Hutagalung** , Ministry of Health (Indonesia), Jakarta, Indonesia

2. **Brendan J. McMorran** , Australian National University, Canberra, Australia

Any reports and responses or comments on the article can be found at the end of the article.

Conclusions: We conclude that splenomegaly, which was a rare clinical finding of these malaria patients, was not associated with thrombocytopenia.

Keywords

thrombocytopenia, splenomegaly, malaria, East Kalimantan

This article is included in the **ICTRIPS 2018** collection.

Corresponding author: Loly R.D. Siagian (lonita_ui@yahoo.com)

Author roles: **Siagian LRD:** Conceptualization, Funding Acquisition, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing; **Lumbantoruan VM:** Data Curation, Writing – Review & Editing; **Hasanah N:** Data Curation, Writing – Original Draft Preparation; **Sihotang FA:** Data Curation, Writing – Original Draft Preparation, Writing – Review & Editing; **Gunawan CA:** Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The Islamic Development Bank funded this study.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2019 Siagian LRD *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

How to cite this article: Siagian LRD, Lumbantoruan VM, Hasanah N *et al.* **Association of thrombocytopenia with splenomegaly in malaria patients in East Kalimantan: A cross-sectional, retrospective study [version 3; peer review: 2 approved]** F1000Research 2019, 7:1832 <https://doi.org/10.12688/f1000research.16606.3>

First published: 21 Nov 2018, 7:1832 <https://doi.org/10.12688/f1000research.16606.1>

REVISED Amendments from Version 2

We revised the wording in our conclusion (on both abstracts and conclusion).

We added some information about the method of determining thrombocyte count.

Any further responses from the reviewers can be found at the end of the article

Introduction

Malaria is still a serious health problem in Indonesia. The 2007 and 2013 Basic Health Surveys of the Health Ministry show that the prevalence of malaria in Indonesia increased from 2.9% to 6.0%¹.

Data from the East Kalimantan Provincial Health Office indicated that there were 7,045 cases of malaria in 2010. This number fluctuated in the following years, with 3,021 cases in 2011, 9,966 cases in 2012 and 2,603 cases in 2013. In terms of Annual Parasitic Incidence (API), in 2014 East Kalimantan was still above the national average with an API of 2.04 per 1000 population, leading to it being categorized as a low cumulative incidence area².

One common finding in malaria is decreased platelet count or so-called thrombocytopenia. This laboratory finding is often confused with other infectious diseases, especially dengue infection in which thrombocytopenia is a major diagnostic parameter. There are several studies that demonstrate thrombocytopenia in malaria patients³⁻⁵, and this is found in both infection with *Plasmodium falciparum* and *Plasmodium vivax*. The results from our previous study demonstrated that from 1041 malaria cases in East Kalimantan, 85% presented with thrombocytopenia of varying degrees⁴. Therefore, thrombocytopenia has been suggested as one important diagnostic parameter in malaria. The mechanism of thrombocytopenia in malaria is still unclear. Several theories, such as mechanical trapping of thrombocytes inside the spleen and immune response that attacks thrombocytes, has been proposed⁵. A study by Coelho *et al.* found that platelet phagocytosis may contribute to thrombocytopenia in vivax malaria⁶.

Splenomegaly is also one common clinical finding in malaria patients. The spleen is part of the reticuloendothelial system, which becomes active in order to get rid of plasmodium-infected erythrocytes. Splenomegaly can also contribute to increased destruction of thrombocytes due to mechanical trapping. Therefore, the aim of the present study was to determine the association of thrombocytopenia with splenomegaly in malaria patients in East Kalimantan.

Methods

Study design and participants

This study was a cross-sectional retrospective study. This study was approved by the Ethical Committee for Health Research at Abdul Wahab Syahrane Public Hospital Samarinda, East Kalimantan (approval number 124/KEPK-AWS/V/2018). Patient consent for the use of their data records was waived by the ethical committee due to the retrospective nature of the study.

Data collection

Data were collected between June and August 2018 from the medical records of patients with malaria during the period of January 2015 to July 2018. We collected clinical and laboratory data of both outpatients and inpatients diagnosed with malaria from four major hospitals in East Kalimantan: Abdul Wahab Sjahranie Hospital in Samarinda, Aji Putri Botung Hospital in Penajam Paser Utara, Abdul Rivai Hospital in Tanjung Redeb, and Panglima Sebaya Hospital in Tanah Grogot.

All patients with malaria, both paediatric and adult patients, were included in the study. Patients were excluded from the study if the necessary data were incomplete or patients were discharged upon own's request during treatment.

In order to collect data, first, the hospital's database was searched for patients diagnosed with malaria. Second, after identifying these patients, the relevant medical records were retrieved which contained age, gender, type of Plasmodium, thrombocyte count, and presence of splenomegaly. Type of Plasmodium was determined using microscopic method by obtaining thick blood smear and staining by Giemsa 3%. The thrombocyte count included in this study was from laboratory data at the time of hospital visit or admission before receiving any treatment. The thrombocyte count was determined using automated haematology analyser of different types and manufacturers available in each hospital.

Data analysis

For descriptive data, we described patients' characteristics that include age, sex, type of Plasmodium, and thrombocyte count on the first day admission. The association between thrombocytopenia and splenomegaly was analyzed by Chi-square test using SPSS 23.0 software. Results were considered statistically significant if $p < 0.05$.

Results

Our study identified a total of 215 malaria patients from January 2015 to July 2018 from four hospitals in East Kalimantan. There were 87.9% (189/215) male and 12.1% (26/215) female patients (Table 1).

The association of thrombocytopenia with splenomegaly in malaria patients shown in Table 2. There were 11 patients with

Table 1. Demographic characteristics of malaria patients included in the study.

Subject Characteristic	Patients (%)
Total number of patients	215
Sex:	
Male	189 (87.9)
Female	26 (12.1)
Type of Plasmodium:	
<i>Plasmodium falciparum</i>	92 (42.8)
<i>Plasmodium vivax</i>	93 (43.2)
Mix infection	10 (4.6)
Unspecified Plasmodium	20 (9.3)
Thrombocyte count (per μL):	
Normal (150,000-400,000)	28 (13.0)
Thrombocytopenia (< 150,000):	187 (87.0)
Mild (100,000-150,000)	34 (18.2)
Moderate (50,000-100,000)	82 (43.8)
Severe (< 50,000)	71 (33.0)

Table 2. Association of thrombocytopenia with splenomegaly in malaria patient.

Thrombocyte count	Splenomegaly		
	Yes	No	
Normal	1	27	Chi-Square test $p = 0.611$
Thrombocytopenia			
Mild	2	32	
Moderate	6	76	
Severe	2	69	
Total	11 (5.1%)	204 (94.8%)	215

splenomegaly and 204 patients without splenomegaly. There was no association between the presence of splenomegaly and thrombocytopenia in these malaria patients ($p=0.661$).

Dataset 1. Data retrieved from the medical records of malaria patients in East Kalimantan, Indonesia, including age, gender, type of Plasmodium, thrombocyte count, and presence of splenomegaly

<http://dx.doi.org/10.5256/f1000research.16606.d225124>

Discussion

We found that the incidence of malaria was higher in males than females in this group of patients, and the parasite infecting the majority of patients was *Plasmodium vivax* (43.2%). This study found that thrombocytopenia affected the majority of malaria patients; thrombocytopenia occurred in 87% of patients, with moderate thrombocytopenia (43.8%) as the majority. This result is in concordance with another study by Arif *et al.*, in India, that found that 79% of patients had moderate thrombocytopenia⁷, while Ansari *et al.* found 69.18%⁸. In the present study, the degree of thrombocytopenia classified to mild, moderate and severe was 18.2%, 43.8%, 33.0%, respectively. If we compare to study of Arif *et al.* that found 33.96%, 51.15% and 14.89%, respectively, we find that the moderate thrombocytopenia was the highest percentage in both studies⁷.

A study by Hanson *et al.* in Vietnam found that thrombocytopenia was a marker of disease severity in adults with *Plasmodium falciparum* infection, but has limited utility in prognostication, triage and management⁹. On the other hand, Rao *et al.* in India found that severe thrombocytopenia showed positive correlation with complicated malaria and become a good predictor for poor prognosis¹⁰. Thrombocyte has an important role in haemostasis. However, study by Abro *et al.* demonstrated

that malaria patients with thrombocytopenia rarely presented with any bleeding manifestations even with platelet count as low as 9,000/ μ L¹¹.

Indeed, splenomegaly is a hallmark of malaria, but the result of this study found that only 11 patients (5.1%) showed splenomegaly. In India, Gupta *et al.* found that only 20% malaria patients had splenomegaly, but there are no information about thrombocyte count in those malaria patients with splenomegaly¹².

In our study, we describe the thrombocyte count in malaria patients with splenomegaly. We found that there was no association between thrombocytopenia with splenomegaly ($p=0.611$). Therefore, we propose that thrombocytopenia is not caused by the mechanical trapping of thrombocytes in the spleen. This result suggests another mechanism of thrombocytopenia that involves immune process, as proposed by Coelho *et al.* in 2013⁶. Until now, definitive mechanism of thrombocytopenia in malaria is still unclear. However, some factors that contribute to thrombocytopenia have been reported, such as decreased thrombopoiesis, peripheral destruction induced by *P. falciparum* and disseminated intravascular coagulation¹¹.

This study has its limitations. Different types of automatic haematology analysers were used in the hospitals and this might contribute to variations in thrombocyte count. Therefore, we suggest the use of a single haematology analyser across hospitals to improve accuracy. In addition, we did not exclude other causes of thrombocytopenia that could coexist with malaria infection, such as viral infection and autoimmune diseases, which would be required to further validate our findings. Finally, the examination of splenomegaly was conducted by different physicians, which might contribute to subjective factors in determining splenomegaly, such as physician's expertise and thoroughness, especially in cases with minor or subclinical splenomegaly.

Overall, we conclude that splenomegaly, which was a rare clinical finding in this set of malaria patients, was not associated with thrombocytopenia.

Data availability

F1000Research: Dataset 1. Data retrieved from the medical records of malaria patients in East Kalimantan, Indonesia, including age, gender, type of Plasmodium, thrombocyte count, and presence of splenomegaly, <https://doi.org/10.5256/f1000research.16606.d225124>¹³

References

1. Basic Health Survey: Health Ministry of Indonesia. 2013.
2. Annual Report East Kalimantan Provincial Health Office. 2013.
3. Gill MK, Makkar M, Bhat S, *et al.*: Thrombocytopenia in Malaria and Its Correlation with Different Types of Malaria. *Ann Trop Med Public Health*. 2013; 6(2): 197–200. [Publisher Full Text](#)
4. Siagian LRD, Asfirizal V, Toruan VDL, *et al.*: Thrombocyte counts in malaria patients at East Kalimantan. *IOP Conf. Series: Earth and Environmental Science*. 2018; 144(1): 012007. [Publisher Full Text](#)
5. Del Portillo HA, Ferrer M, Brugat T, *et al.*: The role of the spleen in malaria. *Cell Microbiol*. 2012; 14(3): 343–35. [PubMed Abstract](#) | [Publisher Full Text](#)

6. Coelho HC, Lopes SC, Pimentel JP, *et al.*: **Thrombocytopenia in *Plasmodium vivax* malaria is related to platelets phagocytosis.** *PLoS One*. 2013; **8**(5): e63410.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Arif M, Jelia S, Meena SR, *et al.*: **A Study of Thrombocytopenia in Malaria and Its Prognostic Significance.** *Int J Res Med Sci*. 2016; **4**(6): 2373–2378.
[Publisher Full Text](#)
8. Ansari S, Khoharo H, Abro A, *et al.*: **Thrombocytopenia in plasmodium falciparum malaria.** *J Ayub Med Coll Abbottabad*. 2009; **21**(2): 145–7.
[PubMed Abstract](#)
9. Hanson J, Phu NH, Hasan MU, *et al.*: **The clinical implications of thrombocytopenia in adults with severe falciparum malaria: a retrospective analysis.** *BMC Med*. 2015; **13**: 97.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Rao BS, Vano MS, Latha GJ, *et al.*: **Incidence, Severity, Prognostic Significance of Thrombocytopenia in Malaria.** *Int J Res Med Sci*. 2015; **3**(1): 116–121.
[Publisher Full Text](#)
11. Abro AH, Ustadi AM, Younis NJ, *et al.*: **Malaria and Hematological Changes.** *Pak J Med Sci*. 2008; **24**(2): 287–291.
[Reference Source](#)
12. Gupta NK, Bansal SB, Jain UC, *et al.*: **Study of thrombocytopenia in patients of malaria.** *Trop Parasitol*. 2013; **3**(1): 58–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Siagian LRD, Lumbantoruan VM, Hasanah N, *et al.*: **Dataset 1 in: Association of thrombocytopenia with splenomegaly in malaria patients in East Kalimantan: A cross-sectional, retrospective study.** *F1000Research*. 2018.
<http://www.doi.org/10.5256/f1000research.16606.d225124>

Open Peer Review

Current Peer Review Status:

Version 3

Reviewer Report 30 October 2019

<https://doi.org/10.5256/f1000research.23205.r55902>

© 2019 McMorran B. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Brendan J. McMorran

Department of Immunology and Infectious Disease, John Curtin School of Medical Research, Australian National University, Canberra, Australia

All my concerns have been addressed, and nothing further to add.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Immunology and genetics (basic research).

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 2

Reviewer Report 16 October 2019

<https://doi.org/10.5256/f1000research.22114.r54854>

© 2019 McMorran B. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Brendan J. McMorran

Department of Immunology and Infectious Disease, John Curtin School of Medical Research, Australian National University, Canberra, Australia

The report is a relatively straight-forward and short description of a prospective malaria patient cohort, with a specific focus on platelet numbers and possible relationships between

thrombocytopenia and the presence of splenomegaly. This is an important question to ask in relation to thrombocytopenia in malaria, since the mechanisms involved are not well-defined – splenic trapping is certainly a valid mechanism to consider. Their platelet data support many previous studies of other patient cohorts showing thrombocytopenia is a common clinical feature in malaria. However, the relatively small number of patients exhibiting splenomegaly (11/204 or 5.1%) precludes making a definitive conclusion about the lack of association with thrombocytopenia. Therefore, I recommend this limitation be included in the abstract and final conclusions of the paper.

Eg. Suggested wording:

Splenomegaly, which was a rare clinical feature of this malaria patient cohort, was not associated with thrombocytopenia.

The methods should include notes about how platelet counts were determined, and the fact that different hematological analyzers were used (this is currently mentioned in the Discussion).

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Partly

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Immunology and genetics (basic research).

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 27 August 2019

<https://doi.org/10.5256/f1000research.22114.r52475>

© 2019 Hutagalung J. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Jontari Hutagalung

Biomedical and Basic Health Technology, National Institute of Health Research and Development, Ministry of Health (Indonesia), Jakarta, Indonesia

Is the work clearly and accurately presented and does it cite the current literature?

Partly

Is the study design appropriate and is the work technically sound?

Partly

Are sufficient details of methods and analysis provided to allow replication by others?

Partly

If applicable, is the statistical analysis and its interpretation appropriate?

Partly

Are all the source data underlying the results available to ensure full reproducibility?

Partly

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 05 June 2019

<https://doi.org/10.5256/f1000research.18149.r40937>

© 2019 Hutagalung J. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Jontari Hutagalung

Biomedical and Basic Health Technology, National Institute of Health Research and Development,

Ministry of Health (Indonesia), Jakarta, Indonesia

This study is important and has a great impact for clinicians in the subject, however I found many lacks in the assessment methodologies, especially:

1. How to define the confirmed cases of this study (microscopic ELISA or PCR).
2. The methodologies to count the thrombocytopenia and splenomegaly.
3. It is important to separate the cases by species of *Plasmodium* and the day of infection.

Additional comments - there are some important things missing in this manuscript that need to be explained by the authors:

- The 1st paragraph; Please use the national Annual Parasite Incidence (API) below 1.00 per 1.000 population or the prevalence < 1%.
- The methodologies need to be addressed, because this is the most important; a) how did the authors use the definition of malaria cases in this study (giemsa 3%)? and b) for the methods of counting the parasite and thrombocytes (after treatment or before treatment, or before and after treatment), did the authors make QA for the test?
- Which prevalence of *P. vivax* is correct – 42.0% (from page 3 in the discussion) or 43.2% (from Table 1)?
- In the discussion I need more explanation about the aims of this study; "Discover the association between thrombocytopenia & splenomegaly", please write about the following: a) the main function of thrombocytes and the kinds of situation risks decreased and for which patient conditions (acute or chronic diseases) and b) the authors should be addressing why their hypothesis was not considered significant.

Please find an annotated copy of the article [here](#) for my full comments.

Is the work clearly and accurately presented and does it cite the current literature?

Partly

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

No

If applicable, is the statistical analysis and its interpretation appropriate?

Partly

Are all the source data underlying the results available to ensure full reproducibility?

Partly

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research